CD274 and non-small cell lung carcinoma: A higher percentage of PD-L1 TPS high (67%) was reported in BRAF non V600E mutant and MET mutant NSCLC in some of the reports (46), and a relatively higher response was seen in patients with PD-L1 TPS high BRAF mutant NSCLC (43), albeit the sample numbers was too small to draw any firm conclusion.